Results with GAZYVA + chlorambucil
chemotherapy vs rituximab + chlorambucil
in previously untreated CLL

How patients responded to GAZYVA + chlorambucil chemotherapy vs rituximab + chlorambucil

In a clinical trial, the combination of GAZYVA and chlorambucil was studied against the combination of rituximab and chlorambucil. Rituximab is another antibody therapy, and chlorambucil is a type of chemotherapy. The results highlighted below were from a clinical trial and may not be the same as what you experience.

GAZYVA taken with chlorambucil chemotherapy versus rituximab + chlorambucil allowed some patients in the study to experience a median of 26.7 versus 14.9 months, respectively, without their cancer getting worse.

GAZYVA + chlorambucil-survival without cancer worsening

These results were from a clinical trial and may not be the same as what you experience.


Nearly 80% of patients had a partial or complete response to GAZYVA + chlorambucil chemotherapy vs rituximab + chlorambucil. Your doctor may refer to this as remission.

GAZYVA CLL-11 study: percentage of patients in complete remission

These results were from a clinical trial and may not be the same as what you experience.

Remission can be partial or complete. Partial remission means the cancer is greatly improved, but evidence of cancer remains. Complete remission means all evidence of the cancer is gone for a period of time.


More than 1 in 4 patients who took GAZYVA + chlorambucil chemotherapy vs rituximab + chlorambucil went into complete remission* for a period of time.

Gazyva versus Rituximab Chlorambucil Therapy Complete Remission Rate

*Includes complete response with incomplete bone marrow recovery.

These results were from a clinical trial and may not be the same as what you experience.

This study included 781 patients:

  • Eight out of 10 patients in the study were 65 years or older
  • They were an average age of 73 years

Patients had other medical conditions such as:

  • High blood pressure
  • Diabetes
  • Heart or kidney conditions